On 29 October 2025, EuroGCT participated in the “Building Bridges for Medicines Justice” conference at the University of Amsterdam, hosting a workshop titled "Is the EU Regulation on HTA Enhancing Equitable Access to Innovative Medicines in Europe? A EuroGCT workshop"
The workshop explores the challenges of enabling equitable patient access to Advanced Therapy Medicinal Products (ATMPs) like gene and cell therapies in the EU. Even when these therapies have central EU authorisation, high costs and differences in how each country decides which treatments to fund can lead to inconsistent access for patients. The workshop formed part of EuroGCT’s Regulatory Engagement Strategy, supporting our mission to connect researchers, regulators, and stakeholders to advance equitable access to gene and cell therapies in Europe.
presentation:
Short introduction to HTAR
Speaker: Niklas Hedberg
Niklas Hedberg is the Chief Pharmacist at the Dental and Pharmaceutical Benefits Agency (TLV) in Sweden. Niklas is the HTAR Coordination Group co-chair for medicinal products. He was the Chair of the Executive Board for EUnetHTA21 (2021-2023) and for EUnetHTA JA 3 (2018- 2021). Niklas has been working with HTA and pricing and reimbursement since 2001.
Please download and view the PDF file of this presentation from the attachment section below.